PHARMACY

PrescribeWellness appoints chief growth officer

BY David Salazar
IRVINE, Calif. — PrescribeWellness has solidified its executive leadership team, announcing Thursday the addition of Kelly Keegan as the company’s chief growth officer. Keegan is tasked with delivering revenue growth in new and existing healthcare verticals, and he joins the company from Xerox Health, where he was SVP sales and business development for the company’s Care Integration Services business. 
 
“We are excited to have Kelly join the leadership team at PrescribeWellness,” PrescribeWellness CEO Al Babbington said. “He possesses a wealth of experience in building relationships within complex market segments. We will leverage his expertise as we boast about our nationwide network of high-performing community pharmacies to payers, self-insured employers and other healthcare businesses.”
 
Before he was at Xerox, Keegan was VP business development for Anthem Blue Cross Blue Shield, where he also served in executive roles in business development and sales, among other divisions. 
 
“Certainly, I was attracted to the rapid growth and impact that PrescribeWellness has had on the healthcare industry,” Keegan said. “Additionally, I was impressed with the people and the way they’ve connected with so many community pharmacies.”
 
Kelly joins Babbington, COO Susan Lewis, chief technology officer Sean Power, CFO Rob Gerger and chief information security officer Todd Plesco on the company’s executive team. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

PrescribeWellness launches Vaccine Complete software solution

BY David Salazar
IRVINE, Calif. — PrescribeWellness on Tuesday announced the introduction of their newest software solution for community pharmacies, Vaccine Complete. The solution is aimed at streamlining the activities that accompany offering year-round immunizations. 
 
“The pharmacist’s role in providing vaccinations in their community continues to expand,” said PrescribeWellness director of clinical services Farah Madhat said. “Increasingly, the overall health of the patient is more important than just counting the correct number of pills for them. Providing the appropriate vaccinations is a key part of overall health. Plus, it allows pharmacists to add valuable services to the patient appointment and practice at the top of their profession.”
 
Vaccine Complete identifies patients eligible for vaccination and includes outreach to patient groups that are recommended to receive certain vaccines. It also automates protocols with prescribers and meets state reporting mandates. Pharmacists will have bi-directional access to their state’s immunization registry through the PrescribeWellness Patient Engagement Center, powered by a partnership with health informatics company Scientific Technologies Corp. The solution was developed using insights from thousands of community pharmacies and PrescribeWellness’ Pharmacy Advisory Board. 
 
“It is a solution for pharmacists that has been built by pharmacists,” PrescribeWellness CEO Al Babbington said. “Our staff of pharmacy clinicians have worked collaboratively with retail community pharmacists to create a solution that solves the challenges that our pharmacists have faced when trying to offer vaccinations.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA expands age indication for Pfizer’s Prevnar 13 vaccine

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has expanded the age indication for Pfizer’s pneumococcal vaccine Prevnar 13. In addition to its previous indications for children aged 6 weeks to 17 years and adults over 50 years of age, the vaccine is now approved for use in adults 18 to 49 years of age. 
 
“This expanded age indication in adults 18 to 49 offers an important public health benefit as appropriate vaccination against S. pneumoniae is critical to reducing the risk of pneumococcal disease, including in those with immunocompromising conditions," Pfizer Vaccines chief medical and scientific affairs officer Dr. Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines.
 
The expanded indication fits closer with the 2012 Centers for Disease Control and Prevention’s Advisory Committee on Immunizations Practice recommendations for adults 19 years of age and older with immunocompromising conditions. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?